By backing DaTSCAN ioflupane I123 injection from GE Healthcare last week, an FDA panel indicated that a molecular imaging agent that allows physicians to see abnormal changes in the brain has clinical value, and that...

Data from 964 patients in ADMIRE-HF, a combination of the identical U.S. and European Phase III MBG311 and MBG312 studies, showed that a high heart to mediastinum ratio (H/M) as measured by imaging with AdreView...

FDA approved an NDA from General Electric's GE Healthcare unit for AdreView as a molecular imaging agent to detect neuroendocrine tumors. The company plans to launch the iobenguane I 123 injection, which has Orphan Drug...

FDA approved an NDA from General Electric (NYSE:GE) for AdreView as a molecular imaging agent to detect neuroendocrine tumors. The company plans to launch the iobenguane I 123 injection, which has Orphan Drug status in...

General Electric's GE Healthcare unit said FDA accepted and granted Priority Review to an NDA for AdreView as a molecular imaging agent to detect neuroendocrine tumors. The company expects a decision within 6 months from...